|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.600 CNY | +2.22% |
|
-2.34% | -11.88% |
Company Valuation: Northeast Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 6,848 | 8,384 | 9,051 | 7,646 | 7,531 | 7,449 |
| Change | - | 22.43% | 7.95% | -15.52% | -1.5% | -1.09% |
| Enterprise Value (EV) 1 | 7,967 | 8,322 | 7,403 | 4,178 | 4,656 | 5,959 |
| Change | - | 4.45% | -11.04% | -43.57% | 11.44% | 27.99% |
| P/E | 507x | 88.9x | 25.2x | 21.4x | 18.2x | 29x |
| PBR | 1.72x | 2.02x | 1.99x | 1.53x | 1.42x | 1.35x |
| PEG | - | 0x | 0x | - | 1.1x | -0.8x |
| Capitalization / Revenue | 0.93x | 1.03x | 1.03x | 0.93x | 1x | 1.05x |
| EV / Revenue | 1.08x | 1.02x | 0.84x | 0.51x | 0.62x | 0.84x |
| EV / EBITDA | 11.6x | 11.6x | 9.9x | 4.62x | 4.57x | 7.76x |
| EV / EBIT | 37.3x | 39.5x | 33.7x | 11.4x | 9.78x | 23.1x |
| EV / FCF | 21.7x | 6.29x | 6.2x | 2.52x | -20.7x | -4.81x |
| FCF Yield | 4.6% | 15.9% | 16.1% | 39.7% | -4.84% | -20.8% |
| Dividend per Share 2 | 0.008 | 0.014 | 0.1 | 0.1 | 0.1 | 0.055 |
| Rate of return | 0.16% | 0.23% | 1.58% | 1.87% | 1.9% | 1.05% |
| EPS 2 | 0.01 | 0.07 | 0.25 | 0.25 | 0.29 | 0.18 |
| Distribution rate | 80% | 20% | 40% | 40% | 34.5% | 30.6% |
| Net sales 1 | 7,384 | 8,145 | 8,809 | 8,243 | 7,503 | 7,075 |
| EBITDA 1 | 688.6 | 715.8 | 747.7 | 904.6 | 1,019 | 767.9 |
| EBIT 1 | 213.6 | 210.6 | 219.6 | 366.2 | 476 | 258.2 |
| Net income 1 | 12.26 | 99.03 | 350.1 | 358.5 | 409.8 | 260.1 |
| Net Debt 1 | 1,119 | -62.17 | -1,647 | -3,468 | -2,876 | -1,491 |
| Reference price 2 | 5.070 | 6.220 | 6.310 | 5.350 | 5.270 | 5.220 |
| Nbr of stocks (in thousands) | 1,350,702 | 1,347,873 | 1,434,316 | 1,429,103 | 1,429,103 | 1,427,088 |
| Announcement Date | 3/16/21 | 3/30/22 | 3/29/23 | 3/29/24 | 4/2/25 | 4/2/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 948M | ||
| 35.93x | 12.68x | 26.75x | 0.57% | 1,067B | ||
| 28.24x | 6.45x | 17.87x | 2.04% | 635B | ||
| 32.64x | 7.65x | 15.73x | 2.65% | 458B | ||
| 19.22x | 4.69x | 11.59x | 2.82% | 347B | ||
| 21.56x | 5.71x | 14.24x | 2.81% | 295B | ||
| 21.1x | 4.45x | 12.31x | 1.98% | 262B | ||
| 14.14x | 5.26x | 10.84x | 3.54% | 216B | ||
| 24.66x | 6.48x | 11.43x | 2.68% | 203B | ||
| -46.58x | 5.59x | 30.88x | 2.55% | 161B | ||
| Average | 16.77x | 6.55x | 16.85x | 2.4% | 364.45B | |
| Weighted average by Cap. | 24.80x | 7.95x | 18.71x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 000597 Stock
- Valuation Northeast Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
















